Search results

We are in the midst of a broad societal change in which women’s sexual problems are becoming increasingly medicalized, characterized as treatable medical conditions and defined and understood as a largely physiologically based disease, called “female sexual dysfunction” (FSD). When a condition is medicalized, a medical framework is used to understand it, and medical interventions are used to treat it. As part of this process, then, over the last several years, researchers and pharmaceutical companies have turned attention to developing medical treatments for FSD. As this medicalization continues to unfold with potentially important impacts, it is crucial that we understand the forces working to shape it.

To investigate the impact of knowledge-intensive FDI in the Chinese pharmaceutical industry, this study analyzes the activity of foreign MNEs operating in this context by exploring their innovative background, the organizational arrangements they use for local knowledge creation and the performance of their local innovative processes. Based on the analysis of the universe of USPTO pharmaceutical patents applied for between 1975 and 2010 and granted to foreign assignees utilizing the work of Chinese inventors, our results show that, while the presence of foreign MNEs in the Chinese pharmaceutical industry entails a strong potential for positive externalities that could enhance the performance of the local innovation system, such externalities do not completely materialize yet, likely because of local actors’ limited absorptive capacity.

Pharmaceutical industry is one of the sunrise industries in the Indian manufacturing sector. It has flourished in the recent past. This chapter makes a comparative analysis of the productivity growth of Indian pharmaceutical industry using production function approach and adopting two distinct measures of labour input and also explains whether the growth and productivity is eco-friendly or not. Annual Survey of Industries (ASI) data is considered as data base and the time period 1980–1981 to 2016–2017 is considered which is sub-divided into four periods (1980–1981 to 1989–1990; 1990–1991 to 1999–2000; 2000–2001 to 2009–2010; and rest of the period). The pattern of result for both the measures are more or less in the same direction. A remarkable growth in total factor productivity (TFP) is observed after the initiation of new economic policy for both the method used. So far as the environmental issues are concerned, this industry seems to have been polluting the environment, as per unit use of energy is increasing over time.

In this chapter, we analyzed the effects of internationalization on innovation, productivity, and firm performance among multinational pharmaceutical companies as representatives of a global knowledge-based industry. The empirical analysis used multiple stepwise regressions based on a sample of 149 firms headquartered in Europe and the US. The results indicate that innovation outcomes are positively correlated to the number of foreign subsidiaries (scope internationalization), whereas surprisingly, formal research and development (R&D) does not seem to directly influence innovation. This suggests that the firms benefit from local overseas subsidiaries to create and implement new innovative offerings. The number of foreign subsidiaries has a U-shaped relationship to patent productivity suggesting that firms can gain advantages by locating cost-intensive activities in low-cost countries and critical tasks in advanced market locations. Firm performance has a U-shaped relationship to sales abroad (scale internationalization) and the relationship is further enhanced by a high focus on R&D. This suggests that sales abroad enable scale economies, where R&D improves quality and relevance of products and thereby boosts performance. Finally, to validate the findings we conducted two semi-structured interviews with representative industry experts and gained further insights for an extended interpretation of results.

Using the pharmaceutical sector as a microcosm of the health sector, we highlight the most prevalent structural and policy issues that make this sector susceptible to corruption and ways in which these vulnerabilities can be addressed. We conducted a literature review of publications from 2004 to 2015 that included books, peer-reviewed literature, as well as gray literature such as working papers, reports published by international organizations and donor agencies, and newspaper articles discussing this topic. We found that vulnerabilities to corruption in the pharmaceutical sector occur due to a lack of good governance, accountability, transparency, and proper oversight in each of the decision points of the pharmaceutical supply chain. What works best to limit corruption is context specific and linked to the complexity of the sector. At a global level, tackling corruption involves hard and soft international laws and the creation of international standards and guidelines for national governments and the pharmaceutical industry. At a national level, including civil society in decision-making and monitoring is also often cited as a positive mechanism against corruption. Anticorruption measures tend to be specific to the particular “site” of the pharmaceutical system and include improving institutional checks and balances like stronger and better implemented regulations and better oversight and protection for “whistle blowers,” financial incentives to refrain from engaging in corrupt behavior, and increasing the use of technology in processes to minimize human discretion. This chapter was adapted from a discussion piece published by Transparency International UK entitled Corruption in the Pharmaceutical Sector: Diagnosing the Challenges.

This chapter offers critique of 2019 Social Responsibility (SR) reports from the five largest American-based pharmaceutical companies (based on revenues and number of employees) and offers suggestions for improved communication about diversity, equity, and inclusion (DEI) practices. Pharmaceutical treatments are an important component of health care. To improve health-care commitment, DEI practices must be front and center for the pharmaceutical industry and communicated via their SR reports targeting stakeholders. While some pharmaceutical companies have made greater strides toward communicating DEI than others, SR reporting often is diminished by lack of clear focus on specific practices. Thus, stakeholders may lack basic understanding of these endeavors and the companies' reputation may suffer the consequences.

The Indian pharmaceutical industry accounts for 8% of global production and exports medicines to over 200 countries. Multinational enterprises (MNEs) enter the Indian market either directly through the establishment of subsidiaries or indirectly through licensing arrangements. However, evidence on MNE’s contribution toward development in India in terms of capability enhancement and linkages or through other spillover effects is limited. The purpose of this research was to generate evidence on (a) contribution of MNEs in the pharmaceutical market in India, (b) nature and impact of foreign direct investment (FDI) inflows in the Indian pharmaceutical sector, (c) contribution of MNEs in R&D and innovation in India, and (d) MNE’s contribution toward introducing new chemical entities (NCEs) and new biological entities (NBEs) in India through a mixed method research design. We conducted an in-depth quantitative analysis on multiple data sets and qualitative interviews of various stakeholders to generate a holistic understanding on the aforementioned research objectives. Our findings suggest that from the perspective of capability enhancement and linkages, the contribution of pharmaceutical MNEs in India is limited. We observed that majority of FDI investments are brownfield against desired greenfield investments. In addition, MNEs are investing far less of profit before tax (PBT) compared with Indian firms on research and development. However, MNEs are contributing significantly toward access to certain pharmaceutical segments like vaccines, hormones, and parenterals, which require sophisticated production facilities, advanced technology, and intellectual capital. Further, MNEs role in innovation and introduction of new medicines (new molecular entity [NME] and NBE New Chemical and Biological Entities (NCEs and NBEs)) in India is significant. We propose that creating a conducive policy environment and predictable regulatory environment can facilitate capability enhancement and linkages through MNEs. Some of the potential policy instruments include appropriate implementation of FDI policy and Intellectual Property Rights (IPR) policy to balance trade and public health.

Taking into consideration that the number of reports about pharmaceutical lobbying activities is increasing (Baleta, 2014; Boseley, 2014) and that the cost of drugs has a direct and powerful impact on both public and private healthcare, there is a need to require pharmaceutical companies to report their activity as well as reflect their considerations about the ethical implications of their work. To answer that need, this chapter explores how pharmaceutical companies communicate their corporate social responsibility activities.

This chapter explores how Pfizer, GlaxoSmithKline and Sanofi (all in the top 10 of US foundations by total giving) use their websites to articulate their CSR strategies. In order to achieve this goal, an exploratory research that combines semantic analysis of the way the mission, vision and objectives are integrated in their strategy was conducted. To do so the researchers saved the text about each company’s mission and vision from their main websites (the .com) and saved all the data associated to CSR communication and reporting included on each company website in a word document. One hundred and ninety-one pages of text were thus collected in August 2013 (67 pages of text for GlaxoSmithKline, 38 pages for Sanofi and 87 pages for Pfizer). Wordle and VOSViewer were used to gain insight into the emerging themes from the textual data collected and therefore compare the similarities and differences between the three companies.

Our findings show a strong emphasis on business-related activities for Sanofi and GSK reflected through the vocabulary used. Additionally, the two companies also portray corporate social responsibility as a tool for image and reputation building and for achieving wider yet profit-driven organisational goals. CSR messages therefore are intended to create and consolidate corporate identity. Moreover, whilst their mission focuses on patients, health, care, and access to medicine, the values are also oriented towards profit making and economic criteria. Pfizer on the other hand, although sharing some of the mission and values with the other two companies, presents itself as a more inclusive organisation with a collaborative environment and research-focused culture.

While limited in scope and sample, this chapter raises many valuable questions for future research about the pharmaceutical sector’s understanding and definition of CSR and their differences and similarities in their online discourse and vocabulary in comparison with other profit-driven industries. Moreover, it raises questions about the style and nature of corporate communications and whether this should be consistent with that associated with CSR as well as whether it imposes the creation of a company-ego.

This chapter promotes an alternative exploratory method of online discourses through computer-aided techniques.

Purpose: The study aims to extract insights into five significant industries, pharmaceutical, space, defence, renewal energy, and information technology (IT), which have huge potential to make India achieving a five trillion-dollar economy in the future.

Design/methodology/approach: The authors focus on future-driven industries which are not only making India a third highest gross domestic product (GDP) producer country but also reviewing the different aspects of these industries and how they can assist India in achieving a five trillion-dollar economies along with determining India’s self-reliance through different governments initiatives in this direction.

Findings: The findings highlight the importance of inclusiveness of policymakers, stakeholders, private players, foreign investors, and the masses. Their significant contributions especially in the pharmaceutical, space, defence, renewal energy, and IT sectors in terms of creativities, innovations, intellect, executions, implementations, and improvements can assist India in achieving its five trillion-dollars economy soon.

Practical implications: This study offers (1) convincing insights into five key industries, pharmaceutical, space, defence, renewal energy, and IT, which have huge potential to increase total GDP volume shortly and (2) the investment areas for the masses where they can see their world not only self-reliant but also will see huge growth in their invested amount in these industries in future.

Originality/value: The insights of five key industries, pharmaceutical, space, defence, renewal energy, and IT, highlight that India has the potential to achieve a five trillion-dollar economy in the future; however, it does not ignore the significant contribution of other industries in making of total GDP.

This investigation set out to uncover whether CSR appeals – socially and/or environmentally oriented efforts promoted as part of a corporation’s advertising campaign – present a fruitful strategy for pharmaceutical manufacturers. This study investigates whether consumers in the two countries are similar with regards to (1) attitudes toward CSR engagement (2) perception of the social engagement of a company (3) perceived product/cause fit and (4) evaluation of CSR versus non-CSR appeals in OTC pharma ads. A field study was conducted (483 subjects; non-student sample) to explore how a standardized promotional message with or without a CSR appeal is perceived in a cross-cultural setting. Results indicate that consumers’ response (with regard to attitudes toward CSR, perceived social engagement by a company, perceived product-cause fit, as well as ad evaluation) all varied by country. Consumer responses were only tested with regard to a fictitious product as well as for one product category. Overall results suggest that CSR messages resonated more with some consumers than with others and, thus, may need to be tailored by market. Apart from a very small number of investigations, neither consumer evaluations of over-the-counter (OTC) drug ads in general, nor responses to CSR ad appeals in particular, have been explored. Thus, this investigation’s primary goal is to explore responses toward CSR messages in non-prescription drug ads in the United States and Brazil.